Literature DB >> 10404599

A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding.

M T Huhtala1, O T Pentikäinen, M S Johnson.   

Abstract

BACKGROUND: Fibroblastic growth factors (FGFs) are a family of cytokines involved in regulation of cell growth, differentiation and chemotaxis in a variety of tissue types. High-affinity FGF receptors (FGFRs) are transmembrane proteins that consist of three extracellular immunoglobulin-like domains, a transmembrane helix and an intracellular protein tyrosine kinase signalling domain. FGFRs are activated through ligand-dependent dimerization that allows trans-autophosphorylation of the tyrosine kinase domains. Heparin or heparin-like molecules, such as heparan sulphate proteoglycans, bind to both FGFs and FGFRs and are required for FGF signal transduction. At present no structure of the ternary complex for FGFR, FGF and heparin exists.
RESULTS: We have used the type-1 interleukin-1 receptor-interleukin-1 beta complex crystal structure, in which both the ligand and the receptor are homologous to those of the FGF-FGFR pair, to identify potential interactions in the FGFR-heparin-FGF ternary complex. A key feature of the modelled complex is the 'electrostatic sandwich' that is formed between the positively charged surfaces of FGF and the receptor, with the negatively charged heparin captured in between. The ternary complex places limits on the range of likely modes of receptor dimerization: one of five different dimeric receptor complexes built from the ternary complex correlates best with the experimental data.
CONCLUSIONS: The ternary complex of FGFR, FGF and heparin, derived on the basis of the homologous interleukin-1 receptor complex, is in agreement with much of the published experimental data, as is the dimeric receptor complex (FGFR-heparin-FGF)2. This work suggests that the FGF interactions seen in crystal structures, which have previously been used to predict the mode of FGF dimerization, might not be relevant to the biologically active dimeric FGFR-heparin-FGF complex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404599     DOI: 10.1016/s0969-2126(99)80091-4

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  4 in total

1.  Structural interactions of fibroblast growth factor receptor with its ligands.

Authors:  D J Stauber; A D DiGabriele; W A Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.

Authors:  Paul K Paik; Ronglai Shen; Michael F Berger; David Ferry; Jean-Charles Soria; Alastair Mathewson; Claire Rooney; Neil R Smith; Marie Cullberg; Elaine Kilgour; Donal Landers; Paul Frewer; Nigel Brooks; Fabrice André
Journal:  Clin Cancer Res       Date:  2017-06-14       Impact factor: 12.531

Review 3.  Coreceptor functions of cell surface heparan sulfate proteoglycans.

Authors:  Kazutaka Hayashida; Rafael S Aquino; Pyong Woo Park
Journal:  Am J Physiol Cell Physiol       Date:  2022-03-23       Impact factor: 5.282

Review 4.  Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.

Authors:  Guihong Liu; Tao Chen; Zhenyu Ding; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  Cell Prolif       Date:  2021-03-02       Impact factor: 6.831

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.